RMA Hunter Valley 2020

DermaSensor’s revolutionary skin cancer technology shines a light on melanoma detection at the Rural Medicine Australia Conference in the Hunter Valley

HUNTER VALLEY, Australia, 24th-27th February 2021: DermaSensor, the medical device company that enables healthcare professionals to efficiently check for skin cancer, will show its revolutionary skin cancer detection product to healthcare professionals at the Rural Medicine Australia conference.

This annual conference and research/scientific health forum is the peak national event for rural and remote doctors of Australia. It is hosted by the Australian College of Rural and Remote Medicine (ACRRM) and the Rural Doctors Association of Australia (RDAA). Almost 900 rural doctors, medical students and other rural health stakeholders from across the country will attend the event.

Rural Medicine Australia 2021 has a packed program full of innovative and informative presentations, interactive workshops and social events, along with many exhibitions.

Kevin Scrimshaw, Commercial Director ANZ, Shannon Whiteley Territory Business Manager NSW, and Martina Clark Territory Business Manager, VIC from the DermaSensor team will present the DermaSensor device, a world-first technology designed to augment clinicians’ assessment of skin lesions.

“We are pleased to return to the Rural Medicine Australia event to present DermaSensor’s technology and explain how it can help rural doctors quickly and effectively check for skin cancer,” explains Kevin.

DermaSensor has managed to miniaturise a device that uses Elastic Scattering Spectroscopy into a handheld device. The technology was pioneered at Boston University and University College London. It uses light to evaluate cellular and subcellular structures of the skin.

The handheld DermaSensor device takes five quick recordings via non-invasive sub-cellular scans. A proprietary algorithm instantly analyses the reflected photons to provide a simple “Higher Risk” or “Lower Risk” output to support a physician’s referral or biopsy decision. DermaSensor complements the expertise and experience to improve the way general practitioners assess the skin. The device is currently listed with the TGA and is available for sale in Australia.

Scroll to Top